| Entry |
|
|---|
| Name |
Sunitinib malate (JAN/USAN);
Sutent (TN)
|
|---|
| Formula |
C22H27FN4O2. C4H6O5
|
|---|
| Exact mass |
532.2333
|
|---|
| Mol weight |
532.5612
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00712): | D06402<JP> |
|
|---|
| Efficacy |
Antineoplastic, Angiogenesis inhibitor, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Gastrotintestinal stromal tumor [DS: H01591] Renal cell carcinoma [DS: H00021] Pancreatic neuroendocrine tumor [DS: H00045] |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE04 Sunitinib
D06402 Sunitinib malate (JAN/USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Sunitinib
D06402 Sunitinib malate (JAN/USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D06402 Sunitinib malate (JAN/USAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
PDGFR family
PDGFR
D06402 Sunitinib malate (JAN/USAN) <JP>
KIT (CD117)
D06402 Sunitinib malate (JAN/USAN) <JP>
FLT3 (CD135)
D06402 Sunitinib malate (JAN/USAN) <JP>
VEGFR family
VEGFR1 (FLT1)
D06402 Sunitinib malate (JAN/USAN) <JP>
VEGFR2 (KDR)
D06402 Sunitinib malate (JAN/USAN) <JP>
VEGFR3 (FLT4)
D06402 Sunitinib malate (JAN/USAN) <JP>
RET family
RET
D06402 Sunitinib malate (JAN/USAN) <JP>
Cytokines and receptors
Cytokines
CSF and other factors
CSF1
D06402 Sunitinib malate (JAN/USAN) <JP>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D06402
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D06402
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D06402
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D06402
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D06402
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 38
1 C8x C 41.1025 -27.7475
2 C8x C 39.9075 -28.4505
3 C8y C 39.9075 -29.8564
4 C8x C 41.1025 -30.5593
5 C8y C 42.2975 -29.8564
6 C8y C 42.2975 -28.4505
7 C2y C 43.7033 -30.2781
8 C5x C 44.4766 -29.1535
9 N1x N 43.7033 -28.0288
10 X F 38.7126 -30.5593
11 O5x O 45.8824 -29.1535
12 C2b C 43.7033 -31.6839
13 C8y C 44.8983 -32.3869
14 C8y C 44.8983 -33.7928
15 C8y C 46.2339 -34.2145
16 C8y C 47.0071 -33.0899
17 N4x N 46.2339 -31.9652
18 C1a C 43.7033 -34.6362
19 C1a C 48.4130 -33.0899
20 C5a C 46.2339 -35.6203
21 O5a O 45.0165 -36.3233
22 N1b N 47.4514 -36.3233
23 C1b C 48.6519 -35.6301
24 C1b C 49.8443 -36.3184
25 N1c N 51.0404 -35.6276
26 C1b C 52.2349 -36.3171
27 C1a C 53.4300 -35.6270
28 C1b C 51.0404 -34.2148
29 C1a C 52.2379 -33.5231
30 C1c C 51.9013 -29.3983
31 C1b C 53.1022 -30.0910
32 C6a C 50.7070 -30.0910
33 O1a O 51.9013 -28.0135
34 C6a C 54.2965 -29.3983
35 O6a O 49.5126 -29.3921
36 O6a O 50.7132 -31.6079
37 O6a O 55.4909 -30.0910
38 O6a O 54.2902 -28.0135
BOND 39
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 7 8 1
9 8 9 1
10 6 9 1
11 3 10 1
12 8 11 2
13 7 12 2
14 12 13 1
15 13 14 2
16 14 15 1
17 15 16 2
18 16 17 1
19 13 17 1
20 14 18 1
21 16 19 1
22 15 20 1
23 20 21 2
24 20 22 1
25 22 23 1
26 23 24 1
27 24 25 1
28 25 26 1
29 26 27 1
30 25 28 1
31 28 29 1
32 30 31 1
33 30 32 1
34 30 33 1 #Up
35 31 34 1
36 32 35 1
37 32 36 2
38 34 37 1
39 34 38 2
|
|---|
